Clik here to view.
Rebiotix raises $8.5m for microbiome therapy
Rebiotix has raised $8.5 million in a $10 million offering, according to a regulatory document that the company filed yesterday with the SEC. The offering, which consists of debt and convertible...
View ArticleClik here to view.
Aerie launches Ph3 trial for Roclatan eye drug in Europe
Aerie Pharmaceuticals (NSDQ:AERI) said today that it launched its European Mercury 3 late-stage trial of Roclatan in patients with open-angle glaucoma or ocular hypertension. The eye drug is a fixed...
View ArticleClik here to view.
Impax settles ‘fax-blasting’ class action suit over EpiPen alternative
Impax Laboratories (NSDQ:IPXL) will pony up $4.8 million to settle claims that it sent blasts of unsolicited faxes to Family Medicine Pharmacy advertising its epinephrine auto-injector, according to a...
View ArticleClik here to view.
Japan approves Medtronic’s In.Pact Admiral drug-coated balloon
Medtronic (NYSE:MDT) said today that its In.Pact Admiral drug-coated balloon won approval from the Japanese Ministry of Health, Labour and Welfar for the treatment of peripheral artery disease in the...
View ArticleClik here to view.
GSK’s triple-med COPD inhaler wins recommendation for approval in EU
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency panel recommended marketing authorization for the Trelegy Ellipta triple-combination inhaler for adults...
View ArticleClik here to view.
Why Takeda thinks partnerships can revive innovation in pharma
Takeda Pharmaceutical (TYO:4502) has been on a partnership spree lately, inking at least 65 collaborations and deal in the last 18 months. Fueling those agreements is a fundamental belief that to...
View ArticleClik here to view.
Teva sells off the rest of its women’s health assets in $2.5B deal
After the company divested its Paragard intrauterine device assets for $1.1 billion in cash last week, Teva Pharmaceuticals (NYSE:TEVA) announced today that it plans to sell off the rest of its global...
View ArticleClik here to view.
FDA approves GSK’s 3-in-1 Trelega Ellipta inhaler
The FDA has approved the triple inhaler developed by GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) to treat chronic obstructive pulmonary disease, the companies reported today. The Trelega...
View ArticleClik here to view.
CIRSE 2017 Round-up: Delcath touts second-gen hemofiltration system in...
Delcath Systems (NSDQ:DCTH) touted data today from a study of its second-generation hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan hydrochloride. The New...
View ArticleClik here to view.
Catalent dishes out $950m for biologics manufacturer
Catalent said today that it plans to purchase Cook Pharmica for $950 million in cash. Cook Pharmica, a unit of privately-held medical device maker Cook Group, is a contract manufacturer that develops...
View ArticleClik here to view.
Following regulatory win, GSK & Innoviva tout data for once-daily triple-med...
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) notched a win this week after the FDA approved its once-daily, triple combination therapy for the treatment of chronic obstructive pulmonary disease....
View ArticleClik here to view.
UK warns about alarm failure for Roche’s insulin pumps
The UK’s Medicines and Healthcare products Regulatory Agency issued a medical device alert for Roche‘s (OTC:RHHBY) Accu-Check Insight insulin pumps today, warning that the device’s audible and...
View ArticleClik here to view.
Reva Medical’s Fantom bioresorbable, drug-eluting vascular scaffold succeeds...
As some companies have worked to improve drug-eluting stents by making them bioresorbable, some voices in the coronary intervention space have expressed concern over the rates of late stent thrombosis...
View ArticleClik here to view.
Convenience, compliance & control: How Insulet is changing insulin delivery tech
Shacey Petrovic spent nearly a decade trying to convince her diabetic father to switch to an insulin pump, rather than inject himself multiple times each day. But he was wary of the tubing and other...
View ArticleClik here to view.
Keeping a patient’s lungs clean & expanded after surgery: a Drug Delivery...
Every year, more than 1 million patients in the U.S. find themselves suffering from respiratory complications following surgery, according to Hill-Rom. These complications come at a cost – to both the...
View ArticleClik here to view.
Gelesis touts study of hydrogel obesity drug
PureTech subsidiary Gelesis today touted results from a pivotal weight-loss study of its obesity drug, Gelesis100. The study met one of its two primary endpoints, with 58% of adults in the treatment...
View ArticleClik here to view.
ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo...
Novocure (NSDQ:NVCR) touted data today from the Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-diagnosed glioblastoma. The analyses were...
View ArticleClik here to view.
Sanofi, Innovation Health to evaluate digital health solutions for Type II...
Innovation Health and Sanofi (NYSE:SNY) said today that the companies are launching a pilot program to evaluate the impact of digital health solutions from One Drop and Common Sensing for people with...
View ArticleClik here to view.
CDC campaign uses testimonials to fight prescription opioid epidemic
The Centers for Disease Control and Prevention today launched a campaign featuring real-life stories of people recovering from opioid-use disorder and people whose loved ones have died due to a...
View ArticleClik here to view.
India gives Abbott a year to withdraw Xience Alpine stent
India’s drug pricing authority has given Abbott (NYSE:ABT) a year to pull its Xience Alpine drug-eluting stent from the market, according to an Indian Economic Times report. The company approached...
View Article